dalteparin has been researched along with Colitis Gravis in 17 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a 22 year-old male with ulcerative colitis in treatment with mesalazine and prednisone presenting with headache and speech disturbances." | 3.81 | [Intracranial sinus venous thrombosis in ulcerative colitis. Report of one case]. ( Bagattini, JC; Calcagno, GP; Chiarella, M; Cohen, H; Forster, TA, 2015) |
| "Heparin could be beneficial to the treatment of active ulcerative colitis because of its anticoagulant, anti-inflammatory and immunomodulatory properties." | 2.72 | Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. ( Evgenidis, N; Giouleme, O; Nikolaidis, N; Papageorgiou, A; Papaioannou, G; Patsiaoura, K; Vassiliadis, T; Zezos, P, 2006) |
| "One hundred patients with active ulcerative colitis (up to six bloody stools per day, no fever, no tachycardia or systemic disturbances) were randomized." | 2.71 | Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. ( Bloom, S; Forbes, A; Irvine, EJ; Kiilerich, S; Langholz, E; Lassen, MR; Leiper, K; Lowson, D; O'Morain, C; Orm, S, 2004) |
| "Inflammatory bowel diseases (IBD)--ulcerative colitis and Crohn's disease--are associated with increased risk for thrombotic complications both in the arterial and venous system." | 1.32 | [Cerebral sinus thrombosis and ulcerative colitis: two cases]. ( Debreczeni, R; Ilniczky, S; Kovács, T; Szirmai, I, 2003) |
| "Ulcerative colitis is a chronic inflammatory bowel disorder of unknown etiology." | 1.31 | Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. ( Alexandrowitz, A; Arber, N; Brazowski, E; Dotan, I; Hallak, A; Halpern, Z; Hershkoviz, R; Knaani, Y; Santo, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Ilniczky, S | 1 |
| Debreczeni, R | 1 |
| Kovács, T | 1 |
| Szirmai, I | 1 |
| Kaya, S | 1 |
| Hatemi, I | 1 |
| Hamzaoglu, I | 1 |
| Uzunismail, H | 1 |
| Vrij, AA | 3 |
| Jansen, JM | 1 |
| Schoon, EJ | 2 |
| de Bruïne, A | 1 |
| Hemker, HC | 3 |
| Stockbrügger, RW | 3 |
| Pastorelli, L | 1 |
| Saibeni, S | 1 |
| Spina, L | 1 |
| Signorelli, C | 1 |
| Celasco, G | 2 |
| de Franchis, R | 1 |
| Vecchi, M | 1 |
| Papa, A | 1 |
| Jones, R | 1 |
| Moro, L | 1 |
| Bozzella, R | 1 |
| Surace, MM | 1 |
| Naccari, GC | 1 |
| Gasbarrini, G | 1 |
| Baumgart, DC | 1 |
| Sbeit, W | 1 |
| Kadah, A | 1 |
| Shafrir, A | 1 |
| Kalisky, I | 1 |
| Mahamid, M | 1 |
| Hazou, W | 1 |
| Katz, L | 1 |
| Mari, A | 1 |
| Khoury, T | 1 |
| Russell, CE | 1 |
| Wadhera, RK | 1 |
| Piazza, G | 1 |
| Calcagno, GP | 1 |
| Bagattini, JC | 1 |
| Forster, TA | 1 |
| Chiarella, M | 1 |
| Cohen, H | 1 |
| Robison, NJ | 1 |
| Dawlabani, N | 1 |
| Lastra, CR | 1 |
| Dhall, G | 1 |
| Zezos, P | 1 |
| Papaioannou, G | 1 |
| Nikolaidis, N | 1 |
| Patsiaoura, K | 1 |
| Papageorgiou, A | 1 |
| Vassiliadis, T | 1 |
| Giouleme, O | 1 |
| Evgenidis, N | 1 |
| Dotan, I | 1 |
| Hallak, A | 1 |
| Arber, N | 1 |
| Santo, M | 1 |
| Alexandrowitz, A | 1 |
| Knaani, Y | 1 |
| Hershkoviz, R | 1 |
| Brazowski, E | 1 |
| Halpern, Z | 1 |
| de Bièvre, MA | 1 |
| Dijkstra, G | 2 |
| de Jong, AE | 2 |
| Oberndorff-Klein Woolthuis, AH | 1 |
| Oberndorff-Klein-Woolthuis, A | 1 |
| Wagenvoord, R | 1 |
| Luo, JY | 1 |
| Zhong, Y | 1 |
| Cao, JC | 1 |
| Cui, HF | 1 |
| Ashizuka, S | 1 |
| Nishiura, R | 1 |
| Ishikawa, N | 1 |
| Yamaga, J | 1 |
| Inatsu, H | 1 |
| Fujimoto, S | 1 |
| Eto, T | 1 |
| Bloom, S | 1 |
| Kiilerich, S | 1 |
| Lassen, MR | 1 |
| Forbes, A | 1 |
| Leiper, K | 1 |
| Langholz, E | 1 |
| Irvine, EJ | 1 |
| O'Morain, C | 1 |
| Lowson, D | 1 |
| Orm, S | 1 |
1 review available for dalteparin and Colitis Gravis
| Article | Year |
|---|---|
Mesenteric venous thrombosis.
Topics: Abdominal Pain; Adult; Anticoagulants; Colectomy; Colitis, Ulcerative; Enoxaparin; Fibrinolysis; Hum | 2015 |
7 trials available for dalteparin and Colitis Gravis
| Article | Year |
|---|---|
Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi.
Topics: Anticoagulants; Capillaries; Colitis, Ulcerative; Humans; Intestinal Mucosa; Nadroparin; Prospective | 2001 |
Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Colitis, Ulcerative; Delayed-Action P | 2008 |
Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Colitis, Ulcerative; Colon; Delayed-A | 2010 |
Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Ami | 2006 |
Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Colonoscopy; Disease Progression; Dose-Response Relationship, Drug; Doub | 2007 |
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
Topics: Adult; Colitis, Ulcerative; Double-Blind Method; Female; Hemostasis; Heparin, Low-Molecular-Weight; | 2007 |
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colitis, Ulcerative; Double-Blind Method; Female; Fibrin | 2004 |
9 other studies available for dalteparin and Colitis Gravis
| Article | Year |
|---|---|
[Cerebral sinus thrombosis and ulcerative colitis: two cases].
Topics: Adult; Anticoagulants; Cerebrovascular Disorders; Colitis, Ulcerative; Female; Humans; Magnetic Reso | 2003 |
Massive haemorrhage induced by low molecular weight heparin in a patient with steroid refractory ulcerative colitis.
Topics: Adult; Anticoagulants; Colitis, Ulcerative; Female; Gastrointestinal Hemorrhage; Humans; Nadroparin; | 2004 |
CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis.
Topics: Administration, Oral; Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparations; Dr | 2010 |
Unawareness of thromboprophylaxis is associated with low venous thromboembolism occurrence in hospitalized patients with acute inflammatory bowel disease flare.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Awareness; Colitis | 2020 |
[Intracranial sinus venous thrombosis in ulcerative colitis. Report of one case].
Topics: Anti-Inflammatory Agents; Anticoagulants; Cerebral Infarction; Colitis, Ulcerative; Enoxaparin; Head | 2015 |
Cerebral sinus thrombosis in a child with active ulcerative colitis and factor V Leiden.
Topics: Anticoagulants; Child; Colitis, Ulcerative; Enoxaparin; Factor V; Heterozygote; Humans; Intracranial | 2009 |
Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Colitis, Ulcerative; Enoxapari | 2001 |
Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
Topics: Administration, Oral; Animals; Anticoagulants; Colitis, Ulcerative; Colon; Dalteparin; Disease Model | 2011 |
Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
Topics: Adolescent; Adult; Aged; Anticoagulants; Benzamidines; Colitis, Ulcerative; Dalteparin; Female; Guan | 2006 |